Form D · Pharmaceuticals
Melior Pharmaceuticals I, Inc.
Exton, PA · CIK 0001532246
Offering snapshot reported Oct 7, 2011 · SEC filing
- Reported sold
- $375K Offering amount: $375K
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Sep 26, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 7, 2011 | Initial | $375,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-166899
The Company is issuing convertible promissory notes. The notes are convertible into shares of Preferred Stock of the Company.
Source: Form D, filed Oct 7, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Adelson | Director |
| Perry Molinoff | Director |
| Toby Moskovits | Director |
| Andrew Reaume | Director, Executive |
| Michael Saporito | Director |
| Jeffrey Vaught | Director |
| Bobba Venkatadri | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
860 Springdale Drive
Exton, PA, 19341
Exton, PA, 19341